AIM: To evaluate the clinical value of CA19-9 in diagnosing and differentiating gastrointestinal tumors and in monitoring patients treated surgically.METHODS: Patients with gastric cancer (n = 70), colorectal cancer (n = 90), pancreatic cancer (n = 7), esophageal cancer (n = 10) and benign disorders (n = 30), and normal adults (n = 111; used as healthy controls), were studied. Fasting blood samples were obtained from each study participant. The serum CA19-9 concentration was measured with radioimmunoassay.RESULTS: The mean CA19-9 level was significantly higher in patients with gastric cancer (170.69 ± 91.45 kU/L) and patients with colorectal cancer (87.21 ± 39.55 kU/L) than in the healthy controls (11.254 ± 6.00 kU/L). Compared with the healthy controls, the CA19-9 level was also much higher in patients with pancreatic cancer (1266.58 ± 521.31 kU/L) (P < 0.01). However, the CA19-9 concentrations in patients with non-recurrent gastric cancer (12.63 ± 3.62 kU/L), colorectal cancer (14.14 ± 3.26 kU/L) and benign disorders (14.23 ± 2.60 kU/L) were statistically similar to those in the healthy controls (P > 0.05). The demarcation value of CA19-9 between negative and positive was < 31.0 kU/L. The sensitivity of CA19-9 for gastric, colorectal, pancreatic and esophageal cancers and for gastrointestinal benign disorders was 47.3%, 50.0%, 83.3%, 20.0% and 0%, respectively. The specificity of CA19-9 for digestive system malignant diseases was 100% for all.
展开▼
机译：目的：评估CA19-9在诊断和鉴别胃肠道肿瘤以及监测手术治疗患者中的临床价值。方法：胃癌（n = 70），大肠癌（n = 90），胰腺癌（n = 7） ），食管癌（n = 10）和良性疾病（n = 30）以及正常成年人（n = 111；用作健康对照）进行了研究。从每个研究参与者获得空腹血液样品。结果：放射免疫法检测血清CA19-9水平。结果：胃癌患者（170.69±91.45kU / L）和结直肠癌患者（87.21±39.55kU / L）的平均CA19-9水平显着高于正常人。健康对照（11.254±6.00 kU / L）。与健康对照组相比，胰腺癌患者的CA19-9水平也高得多（1266.58±521.31 kU / L）（P <0.01）。然而，非复发性胃癌（12.63±3.62 kU / L），结直肠癌（14.14±3.26 kU / L）和良性疾病（14.23±2.60 kU / L）患者的CA19-9浓度与统计学上相似在健康对照组中（P> 0.05）。阴性和阳性之间CA19-9的分界值<31.0 kU / L。 CA19-9对胃癌，大肠癌，胰腺癌和食道癌以及胃肠道良性疾病的敏感性分别为47.3％，50.0％，83.3％，20.0％和0％。 CA19-9对消化系统恶性疾病的特异性均为100％。
展开▼
